UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT ~~REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~ REPORT

~~Date~~Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~Earliest~~the ~~Event~~Securities Exchange ~~Reported):~~Act ~~August 12,~~of ~~2025~~1934

Date of Report (Date of Earliest Event Reported): September 30, 2025

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland(State or Other Jurisdiction of Incorporation)			001-39071(Commission File Number)						N/A(IRS Employer Identification Number)
BiopôleRoute de la Corniche 3B1066 EpalingesSwitzerland(Address of Principal Executive Offices) (Zip Code)						+41 21 653 02 00(Registrant’s Telephone Number)

Switzerland

(State or Other Jurisdiction of Incorporation)

001-39071

(Commission File Number)

N/A

(IRS Employer Identification Number)

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

(Address of Principal Executive Offices) (Zip Code)

+41 21 653 02 00

(Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share	ADCT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 27.0201. ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On ~~August 12~~September 30, 2025, ADC Therapeutics SA (the “Company”) made ~~issued~~available aan ~~press~~updated ~~release~~corporate ~~announcing the Company’s financial results for the second quarter ended June 30, 2025~~presentation. A copy of the ~~press~~corporate ~~release~~presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in ~~this~~these ~~Item~~Items ~~2.02~~ and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description	~~Description~~
99.1	Corporate presentation	~~Press Release dated August 12, 2025~~
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	~~Cover Page Interactive Data File (embedded within the Inline XBRL document)~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADC Therapeutics SA		~~ADC Therapeutics SA~~
Date: August 12, 2025
Date: September 30, 2025
	By:	/s/ Peter J. Graham	~~By:~~	~~/s/ Jose Carmona~~
	Name:	Peter J. Graham	~~Name:~~	~~Jose Carmona~~
	Title:	Chief Legal Officer	~~Title:~~	~~Chief Financial Officer~~

Filing Compare · ADC Therapeutics SA